LFG
RLMD icon

Larson Financial Group’s Relmada Therapeutics RLMD Stock Holding History

Larson Financial Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$324 – 2882
2024
Q3 		$324 Buy
+100
New +$324 ﹤0.01% 2239

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Larson Financial Group's RLMD Position: Q4 2024 in Review

Larson Financial Group sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 100 shares — an estimated $324 sold.

Larson Financial Group first reported a position in RLMD in Q3 2024 and held it in 1 quarter. The position peaked at $324 in Q3 2024. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • Larson Financial Group reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Larson Financial Group sold 100 Relmada Therapeutics shares in Q4 2024, an estimated $324.
  • Larson Financial Group first reported a position in Relmada Therapeutics in Q3 2024 and held it in 1 quarter.
  • Larson Financial Group's Relmada Therapeutics position peaked at $324 in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Larson Financial Group's 13F filing for Q4 2024, filed 7 Feb 2025.